ReviewCancers2020
Non-Invasive Early Molecular Detection of Gastric Cancers.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Utility and clinical effectiveness of liquid biopsy-based DNA methylation testing in early tumor screening and diagnosis, emphasizing older adult populations: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Gastric cancer detection by non-blood-based liquid biopsies: A systematic review looking into the last decade of research.United European gastroenterology journal · 2023Pooled it
- Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.Yonsei medical journal · 2023Trial
- Review
- Use of free blood in the stomach to diagnose gastric mucosal lesions prior to endoscopy: the Sanguis-filum.BMC research notes · 2026Article
- Exosomes and their role in gastric cancer caused by Helicobacter pylori.Molecular biology reports · 2025Review
- Low Preoperative Cachexia Index Is Associated with Severe Postoperative Morbidity in Patients Undergoing Gastrectomy for Gastric Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Screening and evaluation of specific blood MiRNAs as potential biomarkers in diagnostics of gastric Cancer.Scientific reports · 2025Article
- LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.Functional & integrative genomics · 2025Review
- Review
- Liquid biopsy in gastric cancer: A snapshot of the current state of the art.The journal of liquid biopsy · 2025Review
- Integrating Salivary Biomarkers CST4 andClinical Medicine Insights. Oncology · 2025Article
- Gastric Juice Biomarkers in Gastric Cancer: New Trends?Maedica · 2024Article
- Exosome-mediated circGMPS facilitates the development of gastric cancer cells through miR-144-3p/PUM1.Cytotechnology · 2024Article
- Oral microbiota disorder in GC patients revealed by 2b-RAD-M.Journal of translational medicine · 2023Article
- Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer.World journal of clinical cases · 2023Article
- The Human Gastric Juice: A Promising Source for Gastric Cancer Biomarkers.International journal of molecular sciences · 2023Review
- The Mission of Long Non-Coding RNAs in Human Adult Renal Stem/Progenitor Cells and Renal Diseases.Cells · 2023Review
- Regulatory function of DNA methylation mediated lncRNAs in gastric cancer.Cancer cell international · 2022Review
- DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gastric cancer (GC) is a significant source of global cancer death with a high mortality rate, because the majority of patients with GC are diagnosed at a late stage, with limited therapeutic choices and poor outcomes. Therefore, development of minimally invasive or noninvasive biomarkers which are specific to GC is crucially needed. The latest advancements in the understanding of GC molecular landscapes and molecular biological methods have accelerated attempts to diagnose GC at an early stage. Body fluids, including peripheral blood, saliva, gastric juice/wash, urine, and others, can be a source of biomarkers, offering new methods for the early detection of GC. Liquid biopsy-based methods using circulating sources of cancer nucleic acids could also be considered as alternative strategies. Moreover, investigating gastric juices/washes could represent an alternative for the detection of GC via invasive biopsy. This review summarizes recently reported biomarkers based on DNA methylation, microRNA, long noncoding RNA, circular RNA, or extracellular vesicles (exosomes) for the detection of GC. Although the majority of studies have been conducted to detect these alterations in advanced-stage GC and only a few in population studies or early-stage GC, some biomarkers are potentially valuable for the development of novel approaches for an early noninvasive detection of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.